ReviewNeurology international2015
Botulinum Neurotoxin Type A in Neurology: Update.
Review in Neurology international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- EUS-Guided Intragastric Injection of Botulinum Toxin A in the Preoperative Treatment of Super-Obese Patients: a Randomized Clinical Trial.Obesity surgery · 2019Trial
- Brain functional changes in patients with botulism after illegal cosmetic injections of botulinum toxin: A resting-state fMRI study.PloS one · 2018Trial
- Article
- Natural Products and Pharmacological Properties of Symbiotic Bacillota (Firmicutes) of Marine Macroalgae.Marine drugs · 2023Review
- Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults.Toxins · 2023Article
- Research progress in extracorporeal shock wave therapy for upper limb spasticity after stroke.Frontiers in neurology · 2023Review
- Optogenetically controlled human functional motor endplate for testing botulinum neurotoxins.Stem cell research & therapy · 2021Article
- Article
- Patient Knowledge, Attitude and Perceptions towards Botulinum Toxin Treatment for Movement Disorders in India.Journal of movement disorders · 2021Article
- Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective.Frontiers in psychiatry · 2021Review
- Botulinum Neurotoxin-A Injection in Adult Cervical Dystonia and Spastic Paresis: Results From the INPUT (INjection Practice, Usage and Training) Survey.Frontiers in neurology · 2020Article
- Spatial Distribution of Motor Endplates and its Adaptive Change in Skeletal Muscle.Theranostics · 2019Article
- Article
- Article
- Experimental Intrastriatal Applications of Botulinum Neurotoxin-A: A Review.International journal of molecular sciences · 2018Review
- Review
- AbobotulinumtoxinA: A 25-Year History.Aesthetic surgery journal · 2017Review
- The Practical Use of AbobotulinumtoxinA in Aesthetics.Aesthetic surgery journal · 2017Review
- [Use of intracutaneous or subcutaneous botulinum toxin for postherpetic neuralgia].Der Nervenarzt · 2017Review
- Botulinum Toxin Is Effective in the Management of Neurogenic Dysphagia. Clinical-Electrophysiological Findings and Tips on Safety in Different Neurological Disorders.Frontiers in pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper reviews the current and most neurological (central nervous system, CNS) uses of the botulinum neurotoxin type A. The effect of these toxins at neuromuscular junction lends themselves to neurological diseases of muscle overactivity, particularly abnormalities of muscle control. There are seven serotypes of the toxin, each with a specific activity at the molecular level. Currently, serotypes A (in two preparations) and B are available for clinical purpose, and they have proved to be safe and effective for the treatment of dystonia, spasticity, headache, and other CNS disorders in which muscle hyperactivity gives rise to symptoms. Although initially thought to inhibit acetylcholine release only at the neuromuscular junction, botulinum toxins are now recognized to inhibit acetylcholine release at autonomic cholinergic nerve terminals, as well as peripheral release of neuro-transmitters involved in pain regulation. Its effects are transient and nondestructive, and largely limited to the area in which it is administered. These effects are also graded according to the dose, allowing individualized treatment of patients and disorders. It may also prove to be useful in the control of autonomic dysfunction and sialorrhea. In over 20 years of use in humans, botulinum toxin has accumulated a considerable safety record, and in many cases represents relief for thousands of patients unaided by other therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.